Recently, Shenzhen Core Medical Technology Co., Ltd. (hereinafter referred to as "Core Medical") unveiled its implantable Left Ventricular Assist Device (LVAD) Corheart.^®6, Successfully completed the first clinical trial enrollment in Europe, this isThe first European clinical trial of a domestically developed LVAD in China marks an important step for the global application of China's self-developed artificial heart.。

Since its establishment in August 2016, Core Medical has achieved several major breakthroughs with its independently developed artificial heart. AsCurrently the world's smallest and lightest implantable ultra-small fully magnetically suspended artificial heart，Corheart^®6 key performance indicators reach the same level as international similar products, and some technologies even achieve "leading" status, thanks to their excellent clinical performance.Currently has become the artificial heart product with the highest implant volume produced in China.！

Corheart^®6. The smooth progress of clinical trials in Europe will lay a solid and strong foundation for the "Chinese heart" to go international and global. In the future, Core Medical will adhere to its original intention of benefiting heart failure patients worldwide.Accelerate the Promotion of Corheart^®The overseas listing process of Core Medical's product 6, safeguarding the health of heart failure patients worldwide！